• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Wall Street Beat

Senseonics beats The Street in Q1 following Eversense E3 launch

May 11, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Ascensia Diabetes Care, Senseonics

ICU Medical beats The Street in Q1

May 10, 2022 By Sean Whooley

ICU Medical - updated

ICU Medical (Nasdaq:ICUI) reported first-quarter results that came in ahead of the consensus earnings per share forecast. The San Clemente, California-based company yesterday evening posted losses of $38.1 million, or $1.61 per share, on sales of $543.1 million for the three months ended March 31, 2022, for a bottom-line slide into the red on sales […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Vascular, Wall Street Beat Tagged With: ICU Medical, Smiths Medical

Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’

May 5, 2022 By Sean Whooley

Insulet Omnipod 5 Dexcom G6

Insulet (Nasdaq: PODD) reported first-quarter results that topped the consensus forecast, at the same time that it announced its CEO Shacey Petrovic plans to step down for personal family reasons. The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

Tandem stock down after Q1 EPS miss

May 5, 2022 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB

Tandem Diabetes Care (Nasdaq:TNDM) shares are down today, a day after first-quarter results that were mixed compared to the consensus forecast. The San Diego-based automated insulin delivery technology developer posted losses of $14.7 million, or 23¢ per share, on sales of $175.9 million for the three months ended March 31, 2022, for a bottom-line slide […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Tandem Diabetes Care

Avanos rises as Q1 earnings match Wall Street projections

May 4, 2022 By Sean Whooley

Avanos

Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain from losses of […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: avanosmedical

Dexcom dips after hours on Q1 EPS miss, remains confident of U.S. G7 launch this year

April 28, 2022 By Sean Whooley

Dexcom updated logo

Dexcom (Nasdaq:DXCM) shares took a hit after hours today on first-quarter results that fell short of the consensus earnings forecast. DXCM shares were down 6.2% after hours but mostly recovered by the end of the next day. The San Diego-based company posted profits of $97.3 million, or 93¢ per share, on sales of $628.8 million […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Dexcom

Halozyme acquires Antares Pharma for $960M to create drug delivery company

April 13, 2022 By Sean Whooley

Halozyme Antares

Halozyme Therapeutics (Nasdaq:HALO) announced today that it will acquire Antares Pharma (Nasdaq:ATRS) for approximately $960 million. Both companies’ boards of directors approved the transaction, which will see Halozyme acquire Antares for $5.60 per share in cash. According to a news release, the business combination will create a leading drug delivery and specialty product company with […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Antares Pharma, Halozyme Therapeutics

How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD

April 5, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Research & Development, Technology, Wall Street Beat Tagged With: BD, embecta

BD completes spinoff of Embecta diabetes company

April 1, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official. Franklin Lakes, New Jersey-based BD announced its intention to spinoff the diabetes business in May 2021. Near the end of 2021, it unveiled the soon-to-be independent, publicly-traded company’s name as “Embecta,” with plans to complete the spinoff during […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: BD, embecta

Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom

March 30, 2022 By Sean Whooley

Abbott FreeStyle Libre Dexcom G6

Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS), CGM, Dexcom, Reimbursement

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 176
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS